Pfizer Drops $225M Up-Front for Dimebon

After Medivation released its excellent phase IIb results at the Alzheimer’s conference in July, we all knew it was just a matter of time before they partnered the 30+ year old, Russian marketed anti-histamine for the treatment of Alzheimer’s and Huntington’s disease.
That time has come.
Terms:
- $225M up-front
- $500M in milestones
- 60/40 Pfizer/Medivation development cost [...]

Wanna Know Why Drug Discovery/Development Is Hard?

FTY270 (fingolimod), an S1P1 modulator, is a T-cell specific immunosuppressant and is a hot, emerging phase III therapy for MS from Novartis (NVS). So where is the difficulty?
In the Aug. 14, 2008, issue of Nature, scientists from Emory University and the Yerkes Primate Research Center reported that, paradoxically, in a mouse model the drug [...]

Drug Development: From Discovery to NDA

Introduction
The time it takes from starting a program to selling a product can vary but is usually estimated to be around 10 years and the total cost associated with bringing a drug to market is widely cited to be at least $850 million. These numbers outline high stakes and whether you are an [...]

Funding Roundup: IRX, Genesis, Inimex, VeraLight and ONCODESIGN

Busy day on the funding side today. Too many to keep up with and I’m pretty sure I missed a couple but, no time for whining:

ONCODESIGN Secures 4.7M in Financing
VeraLight secures $20 million series C financing for a non-invasive diabetes screening system
IRX therapeutics completes $25 million series A preferred stock offering to continue clinical development [...]